pharma · Parkinson Disease · Tuberculosis · GANX
Gain Therapeutics
Gain Therapeutics is a pharma organization headquartered in Bethesda, USA. It trades on NYSE under ticker GANX. Primary therapeutic focus areas include Parkinson Disease, Tuberculosis, Long-term Care Centres for Old Adul
Bethesda, USA HQ
2017 Founded
28 Employees
Public company Type
GANX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Bethesda, USA
- Founded
- 2017
- Employees
- 28
- Programs
- 4
- Drugs
- 7
- Patents
- 27
Low Dose GT-02287
Phase 2 · small molecule · Parkinson Disease
Low Dose GT-02287 for Parkinson Disease is a Phase 2 program (small_molecule) at Gain Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code GANX-001-V103
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Gain Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Parkinson Disease
- Status
- active
- Trials
- 1